beta

CGEN

Compugen Ltd

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. the company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its pipeline program. the company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its pipeline program and various forms of research and discovery agreements, in both cases providing compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. compugen’s wholly-owned u.s. subsidiary located in south san francisco is developing monoclonal antib

Market Cap: 226 Million

Primary Exchange: NASDAQ

Website: cgen.com

Shares Outstanding: 88.2 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 2.2286851149919773

Sector: Manufacturing

Industry: Biological Product (except Diagnostic) Manufacturing

Ethical Flags

Longest drawdown: 2128 trading days

From: 2014-02-27 To: 2020-04-21

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud